20/20 Biolabs, Inc. (AIDX) Financial Statements
Industry: Testing Laboratories (Services)
In fiscal 2025, 20/20 Biolabs reported revenue of $2.0M. Net income was -$3.7M (a -182.8% net margin), or -$0.76 per diluted share. Gross margin was 29.6% and operating margin was -162.9%. Operating activities generated -$1.9M of cash. At fiscal year end, 20/20 Biolabs held $4.1M in total assets against $4.2M in total liabilities, including $1.0M of cash and equivalents.
Open the full interactive 20/20 Biolabs financials → Quarterly statements, key ratios, valuation history and price charts.
20/20 Biolabs Key Stats
| Share Price | $0.35 |
|---|---|
| Market Cap | $3.8M |
| 52-Week Range | $0.34 – $23.85 |
| Shares Outstanding | 10.8 million (basic, 2026 Q2) |
20/20 Biolabs Income Statement
| FY 2025 | |
|---|---|
| Revenue | $2.0M |
| Gross Profit | $604,541 |
| Operating Income | -$3.3M |
| Pre-Tax Income | -$3.7M |
| Net Income | -$3.7M |
| Diluted EPS | -$0.76 |
20/20 Biolabs Quarterly Results
| 2026 Q1 | 2026 Q2 | |
|---|---|---|
| Revenue | $353,375 | $730,571 |
| Net Income | -$2.2M | -$1.5M |
| Diluted EPS | -$0.28 | -$0.26 |
20/20 Biolabs Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $1.0M |
| Current Assets | $1.5M |
| Total Assets | $4.1M |
| Current Liabilities | $2.5M |
| Total Long-Term Debt | $693,966 |
| Total Liabilities | $4.2M |
| Shareholders' Equity | -$19,225 |
20/20 Biolabs Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$1.9M |
| Cash From Financing | $1.2M |
Figures from 20/20 Biolabs' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full 20/20 Biolabs financials page for every line item.
20/20 Biolabs Company Profile
| Ticker | AIDX |
|---|---|
| Exchange | Nasdaq |
| Industry | Testing Laboratories (Services) |
| Headquarters | Rockville, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001139685 |
Frequently Asked Questions
What was 20/20 Biolabs' revenue in fiscal 2025?
20/20 Biolabs (AIDX) reported revenue of $2.0M for fiscal 2025.
What was 20/20 Biolabs' net income in fiscal 2025?
20/20 Biolabs reported net income of -$3.7M for fiscal 2025.
What was 20/20 Biolabs' earnings per share (EPS) in fiscal 2025?
20/20 Biolabs' diluted EPS was -$0.76 for fiscal 2025 (adjusted for any later stock splits).
What was 20/20 Biolabs' revenue last quarter?
In its most recent reported quarter (2026 Q2), 20/20 Biolabs reported revenue of $730,571.
How much debt does 20/20 Biolabs have?
20/20 Biolabs reported $693,966 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of 20/20 Biolabs are outstanding?
20/20 Biolabs reported a weighted average of 10.8 million basic shares outstanding in 2026 Q2.
What is 20/20 Biolabs' market cap?
Based on its latest closing price, 20/20 Biolabs (AIDX) has a market capitalization of about $3.8M.
When does 20/20 Biolabs' fiscal year end?
20/20 Biolabs' fiscal year end, as registered with the SEC, is December 31.
Where is 20/20 Biolabs headquartered?
20/20 Biolabs lists its business address in Rockville, Maryland in its SEC filings.